Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stromal cells for severe steroid-refractory acute graft-versus-host disease
2012-004915-30Phase 3Terminated
- Sponsor
- HOVON
- Start
- Jan 2013
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Provacel in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by HOVON. Primary endpoint: Response at day 29. Started Jan 2013; status: terminated.
02
Drugs
Provacel
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2012-004915-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004915-30.